Загрузка...
Bevacizumab for Patients with Recurrent Gliomas Presenting with a Gliomatosis Cerebri Growth Pattern
Bevacizumab has been shown to improve progression-free survival and neurologic function, but failed to improve overall survival in newly diagnosed glioblastoma and at first recurrence. Nonetheless, bevacizumab is widely used in patients with recurrent glioma. However, its use in patients with glioma...
Сохранить в:
| Опубликовано в: : | Int J Mol Sci |
|---|---|
| Главные авторы: | , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
MDPI
2017
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5412312/ https://ncbi.nlm.nih.gov/pubmed/28353668 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms18040726 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|